Leerink Swann

Following the market opening Monday morning, the Dow was down about 0.18 percent, roughly 24.75 points. The NASDAQ fell about 0.70 percent, or 22.28 points, while the S&P traded down 0.29 percent, decreasing 4.26 points. Shares of Rock-Tenn (NYSE: RKT) continued to rise midway through Monday,...

Leerink Swann has downgraded VIVUS (NASDAQ: VVUS) from Outperform to Market Perform.

Leerink Swann is bullish on Libigel's prospects for the treatment of female sexual dysfunction.

Leerink Swann is bullish on Libigel's prospects for the treatment of female sexual dysfunction.

Seamus Fernandez of Leerink Swann said on CNBC's Fast Money 360 that he is a buyer of Merck (NYSE: MRK) ahead of earnings. He added that Merck (MRK) is his top pick in the group, and he doesn't expect any surprises in the quarter. Carter Worth of Oppenheimer thinks that whatever happens on earnings...

In a research report released today, analysts at Leerink Swann reiterated their Market Perform rating on shares of Intuitive Surgical (NASDAQ: ISRG). The firm wrote that "ISRG continues to be a unique fast-growing, robotic surgery franchise in MedTech." Intuitive Surgical (ISRG) reported very...

According to analysts at Leerink Swann, the Google Flu Tracker, which tracks search trends in terms of flu activity, shows a continued steep decline of 39% for the week ended March 13, as compared to the 2005-2008 flu season average. The CDC confirmed this finding on March 19, saying that there has...

Analysts Rick Wise and Danielle Antalffy at Leerink Swann have released an update on Medtronic, Inc. (NYSE: MDT). On Friday, Medtronic’s REVO MRI-Safe Pacing System was recommended for approval with conditions by a FDA panel. Analysts believe that this outcome was largely expected. According to...

Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo reiterated their Outperform rating for shares of Incyte Corporation (Nasdaq: INCY) with a price target in "in the high-teens". They said that with an SPA from the FDA for the INCB18424 Phase III program, Incyte Corporation is well on its way...

Analysts Isaac Ro and Jeff Ares at Leerink Swann have released an update on Life Technologies Corp. (NASDAQ: LIFE). The company will soon launch new Attune platform for flow cytometry. Analysts believe that the launch highlights the company’s underappreciated pipeline of new products. Management...

Leerink Swann analysts Gary Nachman and Andrew Finkelstein reiterated their Outperform rating for shares of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and lowered valuation of the company's shares to $6 - $7 per share. The analysts said that there were uncertainties in the Sucampo Pharmaceuticals...

Leerink Swann analysts Howard Liang and Jonathan Eckard rated shares of Medivation, Inc. (Nasdaq: MDVN) a Market Perform with a valuation of $14. The analysts said that the negative readout for the Phase III CONNECTION trial for Dimebon, without any efficacy signal, leads them to believe that...

Leerink Swann analysts Jason Gurda and Neil Bhalodkar maintained their Market Perform rating for shares of Humana Inc. (NYSE: HUM) with a 12-month valuation range of $56-$59. The analysts said that although Humana Inc. is likely to lose 5% of its PFFS members in 2011, it could also gain market...

According to Leerink Swann, the mood at the American Academy of Dermatology (AAD) conference was upbeat and there were signs of gradual improvement in the aesthetics market. “This reinforces the conclusion from the 4Q:09 survey (published in late Jan) that procedure volumes are starting to grow,...